Recro Pharma has made an amendment to its global licensing agreement with Alkermes Pharma Ireland Limited concerning the milestone payments for intravenous (IV) meloxicam. A New Drug Application (NDA) for IV meloxicam is currently under review by the U.S. Food and Drug Administration (FDA) and the company is currently awaiting its assigned PDUFA goal date of March 24, 2019.   Under the prior agreement as amended, Recro Pharma owed Alkermes a milestone payment of $45 million upon approval of IV...